NSCLC Immunotherapy: Transformation of Upfront Therapy – OncLive
OncLive |
NSCLC Immunotherapy: Transformation of Upfront Therapy
OncLive Everett Vokes, MD: Hello, and thank you for joining this OncLive® Peer Exchange® titled “Immuno-Oncology in Advanced Lung Cancer.” We continue to see extraordinary progress in the treatment of advanced non–small cell lung cancer, with … |
Boston Business Journal |
Gene therapy firm Dimension would keep Cambridge office under latest buyout offer
Boston Business Journal A bidding war between California-based Ultragenyx Pharmaceutical against Regenxbio of Maryland could determine the fate of Dimension’s headquarters and employees. Subscribe to get the full story. Already a subscriber? Sign in. Subscribe to get the |
